AR081439A1 - Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata - Google Patents

Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata

Info

Publication number
AR081439A1
AR081439A1 ARP100102410A ARP100102410A AR081439A1 AR 081439 A1 AR081439 A1 AR 081439A1 AR P100102410 A ARP100102410 A AR P100102410A AR P100102410 A ARP100102410 A AR P100102410A AR 081439 A1 AR081439 A1 AR 081439A1
Authority
AR
Argentina
Prior art keywords
composition
prostatic hyperplasia
treatment
degarelix
benigna
Prior art date
Application number
ARP100102410A
Other languages
English (en)
Spanish (es)
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Publication of AR081439A1 publication Critical patent/AR081439A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)
ARP100102410A 2009-07-06 2010-07-06 Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata AR081439A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09251738 2009-07-06
US23581609P 2009-08-21 2009-08-21

Publications (1)

Publication Number Publication Date
AR081439A1 true AR081439A1 (es) 2012-09-05

Family

ID=41112615

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102410A AR081439A1 (es) 2009-07-06 2010-07-06 Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata

Country Status (18)

Country Link
US (2) US20110039787A1 (enExample)
EP (1) EP2451469B1 (enExample)
JP (1) JP2012532188A (enExample)
KR (1) KR20120038956A (enExample)
CN (1) CN102470159A (enExample)
AR (1) AR081439A1 (enExample)
AU (1) AU2010269958A1 (enExample)
BR (1) BR112012000185A2 (enExample)
CA (1) CA2766008A1 (enExample)
IL (1) IL216987A0 (enExample)
MX (1) MX2012000315A (enExample)
NZ (1) NZ597060A (enExample)
RU (1) RU2011152514A (enExample)
SA (1) SA110310575B1 (enExample)
TW (1) TW201105344A (enExample)
UY (1) UY32769A (enExample)
WO (1) WO2011004260A2 (enExample)
ZA (1) ZA201109513B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
WO2010125468A1 (en) * 2009-05-01 2010-11-04 Ferring International Center Sa Composition for the treatment of prostate cancer
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
WO2013178788A2 (en) 2012-06-01 2013-12-05 Ferring B.V. Manufacture of degarelix
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása
US12274680B2 (en) 2022-09-13 2025-04-15 II George William Creasy Treatment of benign prostatic hypertrophy with capsinoids

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JP2719233B2 (ja) * 1991-04-25 1998-02-25 デゲンギ，ロマノ 黄体形成ホルモン放出ホルモン拮抗ペプチド
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
GB0506759D0 (en) * 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
JOP20090061B1 (ar) * 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
EP2257324B1 (en) * 2008-02-11 2016-07-27 Safety Syringes, Inc. Syringe with safety needle guard and clip to prevent release of guard during reconstitution process
WO2010125468A1 (en) * 2009-05-01 2010-11-04 Ferring International Center Sa Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
PL2632934T3 (pl) * 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
ES2655172T3 (es) * 2011-07-15 2018-02-19 Ferring B.V. Procedimiento para preparación temporal de una colonoscopia en la que se administra una composición de picosulfato

Also Published As

Publication number Publication date
IL216987A0 (en) 2012-02-29
KR20120038956A (ko) 2012-04-24
US20110039787A1 (en) 2011-02-17
AU2010269958A1 (en) 2012-01-19
JP2012532188A (ja) 2012-12-13
TW201105344A (en) 2011-02-16
US20120172302A1 (en) 2012-07-05
SA110310575B1 (ar) 2014-10-23
CN102470159A (zh) 2012-05-23
MX2012000315A (es) 2012-02-13
UY32769A (es) 2011-02-28
CA2766008A1 (en) 2011-01-13
BR112012000185A2 (pt) 2017-06-13
RU2011152514A (ru) 2013-08-20
WO2011004260A2 (en) 2011-01-13
WO2011004260A3 (en) 2011-05-19
ZA201109513B (en) 2012-09-26
NZ597060A (en) 2013-05-31
EP2451469B1 (en) 2014-08-20
EP2451469A2 (en) 2012-05-16

Similar Documents

Publication Publication Date Title
AR081439A1 (es) Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
ECSP10010589A (es) Farmaco contra el cancer de higado
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
CU23821A3 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
EP2395834A4 (en) Sodium nitrite-containing pharmaceutical compositions
ME01133B (me) Kombinovana terapija sa peptidnim epoksiketonima
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
AR074471A1 (es) Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
AR078588A1 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
CO5590913A2 (es) Terapia de combinacion antivirica
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
AR108889A1 (es) Combinaciones para el tratamiento del cáncer
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112014009365A2 (pt) método para inibição da atividade de deubiquitinação
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
AR074603A1 (es) Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
UY31826A (es) Compuesto peptídico y su uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure